← Back to Home

Finding a New Path Through an Older Chemotherapy Drug’s RNA Mechanism: Cloverleaf Raises $33 Million to Develop Cancer Therapies

The Yale spinout uses engineered tRNA to inhibit enzymes that cancer cells depend on and is exploring antibody-based delivery strategies. The new funding will advance liver cancer and colorectal cancer programs, but efficacy and safety still need to be validated in human trials.

By SURL BioNews

A chemotherapy drug used for many years may hold clues to developing new therapies. U.S. biotech company Cloverleaf Bio is drawing on the RNA-disrupting anticancer mechanism of 5-fluorouracil (5-FU) to try to target vulnerabilities in cancer cells with engineered RNA molecules. On September 8, the company announced a $33 million seed financing round to advance this research approach, which remains at the preclinical stage.

Based in New Haven, Connecticut, Cloverleaf is a Yale University spinout. The round was led by 4BIO Capital, with participation from AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund. Both BioCentury and MassBio confirmed that the round was oversubscribed. Investment by several pharmaceutical companies before human trials signals research and development interest in the platform, but the investment itself does not demonstrate that the treatment works.

The technology centers on transfer RNA (tRNA). According to BioCentury, the team designs oligonucleotides shaped like tRNA to inhibit enzymes associated with 5-FU’s anticancer activity and attaches these molecules to antibodies that recognize tumors. The company describes its platform as inhibiting multiple RNA-modifying enzymes, seeking to exploit cancer cells’ dependence on these proteins during proliferation to establish a new therapeutic approach.

The funding will support two distinct development paths. According to the company’s announcement, an inhibitory tRNA drug candidate targeting hepatocellular carcinoma is planned to advance into early clinical trials. Another candidate therapy combining an antibody with tRNA targets colorectal cancer and will continue preclinical development. The latter aims to use an antibody to carry the active molecules to tumors. Whether it can achieve sufficient delivery efficiency and selectivity in humans remains to be determined experimentally.

The company says its lead compound, CLB-001, remains active in some drug-resistant cancer cell lines, while animal studies have also provided preliminary signals of tolerability. However, these findings currently come from preclinical data released by the company. The announcement did not provide sample sizes, statistical analyses, or long-term follow-up information sufficient for a full assessment of benefits and risks. The findings therefore cannot establish that patients will benefit or that normal tissues will be unharmed.

The financing also builds on earlier funding and incubation support. BioCentury reported that the team received a $100,000 grant from Eli Lilly as its first external funding while CEO Austin Draycott was still a graduate student at Yale. MassBio noted that Cloverleaf participated in the fall 2023 Drive accelerator. Draycott also partly credits the platform’s launch to SBIR/STTR small-business research and development grants from the U.S. National Cancer Institute.

For Cloverleaf, the new funding gives an idea derived from an existing chemotherapy mechanism a chance to move toward validation in humans. The next key question is whether engineered tRNA can sustain tumor inhibition at effective doses while maintaining an acceptable safety margin. Whether the antibody conjugation strategy offers additional advantages must also be clarified through subsequent research.

References

  1. Hartford Business Journal
  2. BioCentury
  3. MassBio